Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Acute exacerbations of COPD: risk factors for failure and relapse.

Mantero M, Rogliani P, Di Pasquale M, Polverino E, Crisafulli E, Guerrero M, Gramegna A, Cazzola M, Blasi F.

Int J Chron Obstruct Pulmon Dis. 2017 Sep 8;12:2687-2693. doi: 10.2147/COPD.S145253. eCollection 2017. Review.

2.

Network meta-analysis of success rate and safety in antibiotic treatments of bronchitis.

Wang J, Xu H, Liu P, Li M.

Int J Chron Obstruct Pulmon Dis. 2017 Aug 9;12:2391-2405. doi: 10.2147/COPD.S139521. eCollection 2017.

3.

Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics?

Miravitlles M, Anzueto A.

Int J Mol Sci. 2017 Jun 23;18(7). pii: E1344. doi: 10.3390/ijms18071344. Review.

4.

Mucosal-associated invariant T cells in autoimmunity, immune-mediated diseases and airways disease.

Hinks TS.

Immunology. 2016 May;148(1):1-12. doi: 10.1111/imm.12582. Epub 2016 Feb 9. Review.

5.

Fluoroquinolones versus β-Lactam/β-Lactamase Inhibitors in Outpatients with Chronic Obstructive Pulmonary Disease and Pneumonia: A Nationwide Population-Based Study.

Lin KY, Wang CC, Lin CH, Sheng WH, Chang SC.

PLoS One. 2015 Aug 25;10(8):e0136232. doi: 10.1371/journal.pone.0136232. eCollection 2015.

6.

Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease.

Donaldson GC, Law M, Kowlessar B, Singh R, Brill SE, Allinson JP, Wedzicha JA.

Am J Respir Crit Care Med. 2015 Oct 15;192(8):943-50. doi: 10.1164/rccm.201412-2269OC.

7.

Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD.

Wilson R, Anzueto A, Miravitlles M, Arvis P, Haverstock D, Trajanovic M, Sethi S.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 2;10:985-93. doi: 10.2147/COPD.S80926. eCollection 2015.

8.

Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis.

Liu KX, Xu B, Wang J, Zhang J, Ding HB, Ariani F, Qu JM, Lin QC.

J Thorac Dis. 2014 Mar;6(3):221-9. doi: 10.3978/j.issn.2072-1439.2013.11.12.

9.

Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial.

Siva R, Bafadhel M, Monteiro W, Brightling CE, Pavord ID.

Int J Chron Obstruct Pulmon Dis. 2014 Feb 7;9:179-86. doi: 10.2147/COPD.S55419. eCollection 2014.

10.

Gender analysis of moxifloxacin clinical trials.

Chilet-Rosell E, Ruiz-Cantero MT, Pardo MA.

J Womens Health (Larchmt). 2014 Jan;23(1):77-104. doi: 10.1089/jwh.2012.4171. Epub 2013 Nov 1. Review.

11.

Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI).

Chuchalin A, Zakharova M, Dokic D, Tokić M, Marschall HP, Petri T.

BMC Pulm Med. 2013 Jan 23;13:5. doi: 10.1186/1471-2466-13-5.

12.
13.

Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids.

Stefan MS, Rothberg MB, Shieh MS, Pekow PS, Lindenauer PK.

Chest. 2013 Jan;143(1):82-90. doi: 10.1378/chest.12-0649.

14.

Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells.

Yamaya M, Nishimura H, Hatachi Y, Yasuda H, Deng X, Sasaki T, Mizuta K, Kubo H, Nagatomi R.

Antimicrob Agents Chemother. 2012 Aug;56(8):4052-61. doi: 10.1128/AAC.00259-12. Epub 2012 May 14. Erratum in: Antimicrob Agents Chemother. 2012 Oct;56(10):5430.

15.

Epidemiology and management of common pulmonary diseases in older persons.

Akgün KM, Crothers K, Pisani M.

J Gerontol A Biol Sci Med Sci. 2012 Mar;67(3):276-91. doi: 10.1093/gerona/glr251. Epub 2012 Feb 15. Review.

16.

Factors affecting the cost effectiveness of antibiotics.

Simoens S.

Chemother Res Pract. 2011;2011:249867. doi: 10.1155/2011/249867. Epub 2011 Feb 6.

17.

Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.

Wilson R, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, Trajanovic M, Sethi S.

Eur Respir J. 2012 Jul;40(1):17-27. doi: 10.1183/09031936.00090311. Epub 2011 Dec 1. Erratum in: Eur Respir J. 2012 Sep;40(3):800.

18.

A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology.

Wilson R, Anzueto A, Miravitlles M, Arvis P, Faragó G, Haverstock D, Trajanovic M, Sethi S.

Int J Chron Obstruct Pulmon Dis. 2011;6:373-83. doi: 10.2147/COPD.S21071. Epub 2011 Jun 29.

20.

Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life.

Miravitlles M, Llor C, Molina J, Naberan K, Cots JM, Ros F; EVOCA Study Group.

Int J Chron Obstruct Pulmon Dis. 2010 Feb 18;5:11-9.

Supplemental Content

Support Center